Cellectar Biosciences Inc (nasdaq:CLRB) Share Price

Company Profile

Business description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Contact
100 Campus Drive
Florham ParkNJ07932
USA
T: +1 608 441-8120
https://www.cellectar.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11

Recommended

These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.

Morningstar | 11 November 2026

There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.

Malik Ahmed Khan, CFA | 11 November 2026

Strong fundamentals meet a demanding valuation.

Esther Holloway | 11 November 2026

Index	Last price	Change	% Change
All Ordinaries	9,291.30	23.50	0.25%
CAC 40	8,332.87	54.28	0.66%
DAX 40	26,662.77	315.32	1.20%
Dow JONES (US)	52,493.55	261.66	0.50%
FTSE 100	10,835.47	83.88	0.78%
HKSE	24,315.92	241.12	-0.98%
NASDAQ	25,484.07	418.20	1.67%
Nikkei 225	61,248.59	789.01	1.31%
NZX 50 Index	14,179.86	12.45	0.09%
S&P 500	7,623.99	103.06	1.37%
S&P/ASX 200	9,153.20	24.20	0.27%
SSE Composite Index	3,680.64	16.92	0.46%